Compare LTBR & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTBR | LEXX |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.2M | 14.5M |
| IPO Year | N/A | N/A |
| Metric | LTBR | LEXX |
|---|---|---|
| Price | $13.75 | $0.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 11-05-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $705,923.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | N/A | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $4.51 | $0.46 |
| 52 Week High | $31.34 | $2.43 |
| Indicator | LTBR | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 30.06 |
| Support Level | $12.95 | $0.48 |
| Resistance Level | $15.19 | $0.70 |
| Average True Range (ATR) | 1.07 | 0.12 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 14.65 | 6.73 |
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.